Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q1 2023 · 10-Q
Revenue$471.00K$471.00K−6.0% vs Q1 2022 Net Income-$993.00K-$993.00KN/M vs Q1 2022 EPS Diluted-$0.01-$0.01N/M vs Q1 2022 Gross Profit$257,000−21.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
Operating Cash Flow-$902,000N/M Free Cash Flowderived-$939,000N/M Margins · derivedGross margin54.6%−11.1 pt vs Q1 2022
Operating margin-209.3%−50.7 pt vs Q1 2022
Net margin-210.8%−51.9 pt vs Q1 2022
ended Oct 31, 2022 · filed Dec 14, 2022 · 44 d after period end